Post expires at 1:19pm on Thursday June 11th, 2015
Tags: 3D-in vitro co-culture, Amniotic Fluid Stem Cells, Biochemical engineering, Bioprocess; Bioreactor, bone marrow, capping, cardiac disease, cardiomyocytes, cell therapy, cellular biology, Characterisation, Chemical Reprogramming, culture, CYP p450, Decellularized organs, delivery, DNA methylation, drug, Drug Metabolism, Embryonic Stem cells, Epigenetics, ESGRO 2i, glioblastoma, GMP, heart, heart disease, hepatocyte, hESC, heterogeneity, High-throughput efficiency, histone, homing, human embryonic stem cell, human neural stem cells, human pluripotent stem cells, in vitro transcription, Induced pluripotency, Induced Pluripotent Stem Cells, iPS cells, iPSC, kidney regeneration, liver, liver; beta-cell, manufacturing, Mesenchyma stem cell, microRNA, migration, modified nucleotides, Nanog, nanomaterials, neural stem cell, oxidative stress, pancreas, Parkinsons, pluripotency, Pluripotency Regenerative Medicine, Pluripotency; reprogramming; chromatin signatures; DNA replication timing; histone acetyltransferase p30, pluripotent stem cell, Pluripotentcy, poly(A) tail, realistic models, Regenerative Medicine, reprogramming, Stable Karyoytpe, stem cell research, stem cells, STEMCCA, supply chain, synthetic mRNA as drug analogue, toxicity, transcription, translation, variability, whole organ construction, Wnt signalling
Follow Us!